1-(3-(tert-butyldiphenylsilyloxy)phenyl)ethanone | 594813-04-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3-(tert-butyldiphenylsilyloxy)phenyl)ethanone
• 英文别名: 1-(3-(tert-butyldiphenylsilanyloxy)phenyl)ethanone；1-[3-[[(1,1-Dimethylethyl)diphenylsilyl]oxy]phenyl]ethanone；1-[3-[tert-butyl(diphenyl)silyl]oxyphenyl]ethanone
• CAS: 594813-04-4
• 化学式: C₂₄H₂₆O₂Si
• 分子量: 374.555
• InChiKey: VNEUIFRINQADQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.83
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-(tert-butyldiphenylsilyloxy)phenyl)ethanone 在 dirhodium(II) tetracarboxylate 、 potassium tert-butylate 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 异丙醇 为溶剂， 反应 5.0h， 生成 (1R,2R)-ethyl 2-(3-hydroxyphenyl)-2-methylcyclopropanecarboxylate
  参考文献：
  名称：

  Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

  摘要：

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,

  DOI：

  10.1021/ml300427u
• 作为产物：
  描述：

  3-羟基苯乙酮 、 叔丁基二苯基氯硅烷 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以95.8%的产率得到1-(3-(tert-butyldiphenylsilyloxy)phenyl)ethanone
  参考文献：
  名称：

  [EN] BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
  [FR] DERIVES DE BENZOFURANE ET DE BENZOTHIOPHENE UTILISES DANS LE TRAITEMENT DE TROUBLES HYPERPROLIFERATIFS

  摘要：

  这项发明涉及一般式的新型苯并呋喃和苯并噻吩衍生物及其用于治疗高增殖性疾病的用途。

  公开号：

  WO2003072561A1

文献信息

• [EN] BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS<br/>[FR] DERIVES DE BENZOFURANE ET DE BENZOTHIOPHENE UTILISES DANS LE TRAITEMENT DE TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2003072561A1

  公开（公告）日：2003-09-04

  This invention relates to novel benzofuran and benzothiophene derivatives of the general formula and their use for the treatment of hyper-proliferative disorders.

  这项发明涉及一般式的新型苯并呋喃和苯并噻吩衍生物及其用于治疗高增殖性疾病的用途。
• WO2008/25509
  申请人：——

  公开号：——

  公开（公告）日：——
• <i>O</i>-Acetyl Oximes as Transformable Directing Groups for Pd-Catalyzed C−H Bond Functionalization
  作者：Sharon R. Neufeldt、Melanie S. Sanford

  DOI：10.1021/ol902720d

  日期：2010.2.5

  O-Acetyl oximes serve as effective directing groups for Pd-catalyzed sp(2) and sp(3) C-H functionalization reactions. The C-H functionalization products can be subsequently transformed into ortho- or beta-functionalized ketones, alcohols, amines, and heterocycles.
• Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles
  作者：Yingcai Wang、Jiwen (Jim) Liu、Paul J. Dransfield、Liusheng Zhu、Zhongyu Wang、Xiaohui Du、Xianyun Jiao、Yongli Su、An-rong Li、Sean P. Brown、Annie Kasparian、Marc Vimolratana、Ming Yu、Vatee Pattaropong、Jonathan B. Houze、Gayathri Swaminath、Thanhvien Tran、Khanh Nguyen、Qi Guo、Jane Zhang、Run Zhuang、Frank Li、Lynn Miao、Michael D. Bartberger、Tiffany L. Correll、David Chow、Simon Wong、Jian Luo、Daniel C.-H. Lin、Julio C. Medina

  DOI：10.1021/ml300427u

  日期：2013.6.13

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,